Physician

Abdul H Bahrainwala, M.D.

According to 2025 Medicare claims, Abdul Bahrainwala, M.D. (NPI: 1265465769) practices allergy/immunology in the Warren-Troy-Farmington Hills, MI market, with the plurality of this provider's patient population coming from Oakland, MI. This provider's primary affiliated billing organization is ALLERGY & ASTHMA ASSOCIATES OF MI PC (NPI: 1871526459; TIN: 382904386) and primary practice location at 48073-6711.

Bahrainwala's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 392 traditional Medicare patients, billed 27,730 HCPCS/CPT codes, and received $631,276 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,240 prescription claims across 556 beneficiaries totaling $998,400 in drug costs, led by Dupixent Syringe (Dupilumab). DME data shows 201 claims. Open Payments data shows 124 records totaling $2,966. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $143,799 to $998,400. In contrast, DME billing represents a smaller volume and rose steadily, from $1,831 to $3,162.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	359	41,241	$735,872
2016	402	39,275	$711,578
2017	412	38,428	$740,468
2018	418	35,621	$706,470
2019	475	36,936	$791,581
2020	451	33,362	$822,354
2021	441	33,666	$909,831
2022	418	32,150	$822,659
2023	404	33,830	$753,111
2024	392	27,730	$631,276

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	298	1,378	$143,799
2016	334	1,481	$176,070
2017	418	1,960	$282,706
2018	530	2,765	$443,624
2019	556	2,420	$422,215
2020	675	3,013	$595,225
2021	609	2,577	$745,208
2022	494	1,961	$636,827
2023	494	2,116	$1,045,247
2024	556	2,240	$998,400

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	128	$1,972
2016	11	87	$97,259
2017	33	120	$32,794
2018	48	141	$31,416
2019	39	156	$31,115
2020	47	219	$35,727
2021	41	208	$89,169
2022	55	292	$135,646
2023	15	251	$167,838
2024	N/R	201	$188,489

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	345	839	$64
94726	Test to determine lung volumes using sensors	84	85	$40
94060	Test to measure expiratory airflow and volume changes before and after medication administration	242	455	$28
95165	Professional service for preparation and provision of 1 or more antigens	177	4,799	$11
95117	Professional service for multiple injections of allergen	167	2,809	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Syringe	Dupilumab	69	1,932	$245,167
Nucala	Mepolizumab	20	560	$170,424
Tezspire	Tezepelumab-Ekko	28	784	$113,166
Dupixent Pen	Dupilumab	30	840	$111,942
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	105	3,810	$75,970

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	23	$90,944
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	22	$57,513
J1557	Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	12	$31,421
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	14	$4,615
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	23	$1,652

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	124	$2,966	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdul H. Bahrainwala, M.D.?

Tedicare shows public-source Medicare data for Abdul H. Bahrainwala, M.D. (NPI 1265465769), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdul H. Bahrainwala, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Abdul H. Bahrainwala, M.D.?

Abdul H. Bahrainwala, M.D. is linked to ALLERGY & ASTHMA ASSOCIATES OF MI PC (billing NPI 1871526459) in the available physician profile data.

Does Abdul H. Bahrainwala, M.D. have Open Payments data?

Abdul H. Bahrainwala, M.D. has 124 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.